Targeting WEE1 Kinase in Gynecological Malignancies
Wenhao Zhang,Qingli Li,Rutie Yin
DOI: https://doi.org/10.2147/dddt.s462056
IF: 4.3188
2024-06-21
Drug Design Development and Therapy
Abstract:Wenhao Zhang, 1, 2 Qingli Li, 1, 2, &ast Rutie Yin 1, 2, &ast 1 Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, People's Republic of China; 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Rutie Yin, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China, Email Qingli Li, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, People's Republic of China, Email WEE1 kinase is involved in the G2/M cell cycle checkpoint control and DNA damage repair. A functional G2/M checkpoint is crucial for DNA repair in cancer cells with p53 mutations since they lack a functional G1/S checkpoint. Targeted inhibition of WEE1 kinase may cause tumor cell apoptosis, primarily, in the p53-deficient tumor, via bypassing the G2/M checkpoint without properly repairing DNA damage, resulting in genome instability and chromosomal deletion. This review aims to provide a comprehensive overview of the biological role of WEE1 kinase and the potential of WEE1 inhibitor (WEE1i) for treating gynecological malignancies. We conducted a thorough literature search from 2001 to September 2023 in prominent databases such as PubMed, Scopus, and Cochrane, utilizing appropriate keywords of WEE1i and gynecologic oncology. WEE1i has been shown to inhibit tumor activity and enhance the sensitivity of chemotherapy or radiotherapy in preclinical models, particularly in p53-mutated gynecologic cancer models, although not exclusively. Recently, WEE1i alone or combined with genotoxic agents has confirmed its efficacy and safety in Phase I/II gynecological malignancies clinical trials. Furthermore, it has become increasingly clear that other inhibitors of DNA damage pathways show synthetic lethality with WEE1i, and WEE1 modulates therapeutic immune responses, providing a rationale for the combination of WEE1i and immune checkpoint blockade. In this review, we summarize the biological function of WEE1 kinase, development of WEE1i, and outline the preclinical and clinical data available on the investigation of WEE1i for treating gynecologic malignancies. Keywords: WEE1 inhibitor, cell cycle, gynecological malignancies, adavosertib, clinical trials Tyrosine kinase WEE1 is crucial for DNA damage repair (DDR) and cell cycle regulation. A family of 14 serine/threonine protein kinases known as cyclin-dependent kinases (CDKs), regulate cell entry into different cell cycle phases by binding to cyclin subunits and phosphorylation. 1 For example, CDK1 binds to cyclin B, regulates the G2/M checkpoint, and hinders DNA-damaged cells from going through mitosis. Through phosphorylation of CDK1 at tyrosine residue 15 (Y15), WEE1 keeps CDK1 in an inactive state before mitosis, which induces G2/M cell cycle arrest in response to DNA damage, and provides time for DDR. 2 Targeted inhibition of WEE1 results in elevated CDK1 activity, and cells pass the G2/M checkpoint without sufficient DDR, which eventually results in genomic instability, aberrant mitosis, and cellular death. 3 In addition, previous studies have revealed that WEE1 is involved in homologous recombination (HR) repair, replication fork stabilization, and cell size coordination. 4–6 This effect is more prominent in tumor cells, as they often have tumor suppressor p53 protein deletion, resulting in a deregulated G1 checkpoint and relying heavily on the G2/M checkpoint to avert excessive DNA damage, aberrant mitosis, and cell death. Interestingly, as the most lethal gynecological cancer, the majority of high-grade serous ovarian cancer (OC) and uterine serous carcinoma (USC) have TP53 mutations. 7,8 Moreover, human papillomavirus (HPV)-related cervical cancer (CC) exhibits high levels of replication stress due to the loss of p53 control of the G1/S checkpoint caused by HPV E6 and E7 proteins. 9 The hallmark features of cervical, ovarian and uterine cancer make them vulnerable to therapeutic interventions on the G2/M checkpoint, making WEE1 a compelling new target for treating these tumors. The effects of WEE1 inhibition in gynecologic tumors have been shown in a number of preclinical investigations, and positive clinical trial data have also been released. In the current review, we enumerate the biological role of WEE1 kinase and the potential of WEE1 inhibitor (WEE1i) for treating gynecological malignancies and whether it could be transla -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal